Skip to main content Accessibility help
×
Home

Drug disposition in obesity and protein–energy malnutrition

  • Joseph I. Boullata (a1)

Abstract

Clinical response to medication can differ between patients. Among the known sources of variability is an individual's nutrition status. This review defines some pharmacokinetic terms, provides relevant body size metrics and describes the physiologic influences of protein–energy malnutrition and obesity on drug disposition. Weight-based drug dosing, which presumes a healthy BMI, can be problematic in the protein–energy malnourished or obese patient. The use of total body weight, lean body weight, or an adjusted body weight depends on the drug and how it is differently handled in malnutrition or obesity. Most of the recognized influences are seen in drug distribution and drug elimination as a result of altered body composition and function. Distribution characteristics of each drug are determined by several drug-related factors (e.g. tissue affinity) in combination with body-related factors (e.g. composition). Drug elimination occurs through metabolic and excretory pathways that can also vary with body composition. The current data are limited to select drugs that have been reported in small studies or case reports. In the meantime, a rational approach to evaluate the potential influences of malnutrition and obesity can be used clinically based on available information. Antimicrobials are discussed as a useful example of this approach. Further advancement in this field would require collaboration between experts in body composition and those in drug disposition. Until more data are available, routine monitoring by the clinician of the protein–energy malnourished or obese patient receiving weight-based drug regimens is necessary.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Drug disposition in obesity and protein–energy malnutrition
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Drug disposition in obesity and protein–energy malnutrition
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Drug disposition in obesity and protein–energy malnutrition
      Available formats
      ×

Copyright

Corresponding author

Corresponding author: Associate Professor Joseph I. Boullata, fax +1 215 573 7522, email boullata@nursing.upenn.edu

References

Hide All
1.Rowland, M & Tozer, TN (editors) (2010) Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, 4th ed. New York, NY: Lippincott, Williams & Wilkins.
2.Santos, CA & Boullata, JI (2005) An approach to evaluating drug–nutrient interactions. Pharmacotherapy 25, 17891800.
3.Boullata, JI (2010) An introduction to drug–nutrient interactions. In Handbook of Drug-Nutrient Interactions, 2nd ed., pp. 326 [Boullata, JI and Armenti, VT, editors]. New York, NY: Humana Press.
4.Mehta, S (1990) Malnutrition and drugs: clinical implications. Dev Pharmacol Ther 15, 159165.
5.Walter-Sack, I & Klotz, U (1996) Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 31, 4764.
6.Compher, CW & Boullata, JI (2010) Influence of protein-calorie malnutrition on medication. In Handbook of Drug–Nutrient Interactions, 2nd ed., pp. 137165 [Boullata, JI and Armenti, VT, editors]. New York, NY: Humana Press.
7.Boullata, JI (2010) Influence of overweight and obesity on medication. In Handbook of Drug–Nutrient Interactions, 2nd ed., pp. 167205 [Boullata, JI and Armenti, VT, editors]. New York, NY: Humana Press.
8.Conney, AH & Burns, JJ (1962) Factors influencing drug metabolism. Adv Pharmacol 1, 3158.
9.Cheymol, G (2000) Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 39, 215231.
10.Summers, LK, Samra, JS, Humphreys, SM et al. . (1996) Subcutaneous adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci 91, 679683.
11.Wada, DR, Bjorkman, S, Ebling, WF et al. . (1997) Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. Anesthesiology 87, 884899.
12.Torún, B (2006) Protein–energy malnutrition. In Modern Nutrition in Health and Disease, 10th ed., pp. 881908 [Shils, ME, Shike, M, Ross, AC et al. , editors]. Philadelphia, PA: Lippincott, Williams & Wilkins.
13.Rolfes, SR, Pinna, K & Whitney, E (2006) Understanding Normal and Clinical Nutrition, 7th ed. Wadsworth, OH: West Wadsworth.
14.Gross, R & Webb, P (2006) Wasting time for wasted children: severe child undernutrition must be resolved in non-emergency settings. Lancet 367, 12091211.
15.Mokdad, AH, Ford, ES, Bowman, BA et al. . (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289, 7679.
16.Mensah, GA, Mokdad, AH, Ford, E et al. . (2004) Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin 22, 485504.
17.Allison, DB, Fontaine, KR, Manson, JE et al. . (1999) Annual deaths attributable to obesity in the United States. JAMA 282, 15301538.
18.Centers for Disease Control and Prevention. Overweight and Obesity. Updated May 2010. http://www.cdc.gov/nccdphp/dnpa/obesity/index.htm (accessed 31 May 2010).
19.Stratton, RJ & Elia, M (2006) Deprivation linked to malnutrition risk and mortality in hospital. Br J Nutr 96, 870876.
20.Santry, HP, Gillen, DL & Lauderdale, DS (2005) Trends in bariatric surgical procedures. JAMA 294, 19091917.
21.Goutelle, S, Bourguignon, L, Bertrand-Passeron, N et al. (2009) Visual estimation of patients' body weight in hospital: the more observers, the better? Pharm World Sci 31, 422425.
22.Keys, A, Fidanza, F, Karvonen, MJ et al. . (1972) Indices of relative weight and obesity. J Chronic Dis 25, 329343.
23.National Institutes of Health Consensus Development Panel on the Health Implications of Obesity (1985) Health implications of obesity: National Institutes of Health consensus development conference statement. Ann Intern Med 103, 10731077.
24.Knapp, TR (1983) A methodological critique of the ‘ideal weight’ concept. JAMA 250, 506510.
25.Robinson, JD, Lupkiewicz, SM, Palenik, L et al. . (1983) Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm 40, 10161019.
26.Hamwi, GJ (1964) Therapy: changing dietary concepts. In Diabetes Mellitus: Diagnosis and Treatment, pp. 7378. [Danowski, TS]. New York, NY: American Diabetes Association.
27.Devine, BJ (1974) Gentamicin therapy. Drug Intell Clin Pharm 8, 650655.
28.Shen, W, Wang, ZM, Punyanita, M et al. . (2003) Adipose tissue quantification by imaging methods: a proposed classification. Obes Res 11, 516.
29.Sarkar, SR, Kuhlmann, MK, Kotanko, P et al. . (2006) Metabolic consequences of body size and body composition in hemodialysis patients. Kidney Int 70, 18321839.
30.Green, B & Duffull, S (2002) Caution when lean body weight is used as a size descriptor for obese subjects. Clin Pharmacol Ther 72, 743744.
31.Barras, MA, Duffull, SB, Atherton, JJ et al. . (2008) Individualized compared with conventional dosing of enoxaparin. Clin Pharmacol Ther 83, 882888.
32.Thompson, PA, Rosner, GL, Matthay, KK et al. . (2009) Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol 64, 243251.
33.James, WP (1976) Research on Obesity. London, UK: Her Majesty's Stationary Office.
34.Hume, R & Weyers, E (1971) Relationship between total body water and surface area in normal and obese subjects. J Clin Pathol 24, 234238.
35.Boddy, K, King, PC, Hume, R et al. . (1972) The relation of total body potassium to height, weight, and age in normal adults. J Clin Pathol 25, 512517.
36.Womersley, J, Boddy, K, King, PC et al. . (1972) A comparison of the fat-free mass of young adults estimated by anthropometry, body density and total body potassium content. Clin Sci 43, 469475.
37.Green, B & Duffull, SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58, 119133.
38.Janmahasatian, S, Duffull, SB, Ash, S et al. . (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44, 10511065.
39.La Colla, L, Albertin, A, La Colla, G et al. . (2010) Predictive performance of the ‘Minto’ remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass. Clin Pharmacokinet 49, 131139.
40.Morgan, DJ & Bray, KM (1994) Lean body mass as a predictor of drug dosage: implications for drug therapy. Clin Pharmacokinet 26, 292307.
41.Nawaratne, S, Brien, JE, Seeman, E et al. . (1998) Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol 46, 447452.
42.Janmahasatian, S, Duffull, SB, Chagnac, A et al. . (2008) Lean body mass normalizes the effect of obesity on renal function [letter]. Br J Clin Pharmacol 65, 964965.
43.Detsky, AS, McLaughlin, JR & Baker, JP (1987) What is subjective global assessment of nutritional status? J Parenter Enteral Nutr 11, 813.
44.Hoffer, JT (1999) Metabolic consequences of starvation. In Modern Nutrition in Health and Disease, 9th ed., pp. 645666 [Shils, ME, Olson, JA, Shike, M et al. , editors]. Philadelphia, PA: Lippincott, Williams & Wilkins.
45.Owen, OE, Felig, P, Morgan, AP et al. . (1969) Liver and kidney metabolism during prolonged starvation. J Clin Invest 48, 574583.
46.Bravo, ME, Arancibia, A, Jarpa, S et al. . (1982) Pharmacokinetics of gentamicin in malnourished infants. Eur J Clin Pharmacol 21, 499504.
47.Samotra, K, Gupte, S & Raina, RK (1985) Pharmacokinetics of gentamicin in protein–energy malnutrition. Eur J Clin Pharmacol 29, 255256.
48.Ronchera-Oms, CL, Tormo, C, Ordovas, JP et al. . (1995) Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. J Clin Pharm Ther 20, 253258.
49.Lares-Asseff, I, Zaltzman, S, Guillé, MGP et al. . (1997) Pharmacokinetics of cyclosporine as a function of energy-protein deficiency in children with chronic renal failure. J Clin Pharmacol 37, 179185.
50.Buchanan, N, Davis, MD & Eyberg, C (1979) Gentamicin pharmacokinetics in kwashiorkor. Br J Clin Pharmacol 8, 451453.
51.Mehta, S, Nain, CK, Sharma, B et al. . (1982) Disposition of four drugs in malnourished children. Drug-Nutrient Interact 1, 205211.
52.Berlinger, WG, Park, GD & Spector, R (1985) The effect of dietary protein on the clearance of allopurinol and oxypurinol. N Engl J Med 313, 771776.
53.Ashton, R, Boime, P, Alemayehu, E et al. . (1993) Decreased chloramphenicol clearance in malnourished Ethiopian children. Clin Pharmacol 45, 181186.
54.Lee, JH, Suh, OK & Lee, MG (2004) Pharmacokinetic changes in drugs during protein-calorie malnutrition: correlation between drug metabolism and hepatic microsomal cytochrome P450 isozymes. Arch Pharm Res 27, 693712.
55.Cho, MK, Kim, YG, Lee, MG et al. . (1999) Suppression of rat hepatic cytochrome P450s by protein-calorie malnutrition: complete or partial restoration by cysteine or methionine supplementation. Arch Biochem Biophys 372, 150158.
56.Sartorio, A, Malavolti, M, Agosti, F et al. . (2005) Body water distribution in severe obesity and its assessment from eight-polar bioelectrical impedance analysis. Eur J Clin Nutr 59, 155160.
57.Forbes, GB & Welle, SL (1983) Lean body mass in obesity. Int J Obes 7, 99107.
58.Rosell, S & Belfrage, E (1979) Blood circulation in adipose tissue. Physiol Rev 59, 10781104.
59.Gallagher, D, Visser, M & Sepulveda, D (1993) How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 22, 228239.
60.Fernández, JR, Heo, M, Heymsfield, SB et al. (2003) Is percentage body fat differentially related to body mass index in Hispanic Americans, African Americans, and European Americans? Am J Clin Nutr 77, 7175.
61.McLeay, SC, Morrish, GA, Kirkpatrick, CM et al. . (2009) Encouraging the move towards predictive population models for the obese using propofol as a motivating example. Pharm Res 26, 16261634.
62.Han, PY, Duffull, SB, Kirkpatrick, CMJ et al. . (2007) Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 82, 505508.
63.Greenblatt, DJ, Abernathy, DR, Locniskar, A et al. . (1984) Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61, 2735.
64.Flechner, SM, Kilbeinsson, ME, Tam, J et al. . (1989) The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation 47, 806810.
65.Milsap, RL, Plaisance, KI & Jusko, WJ (1984) Prednisolone disposition in obese men. Clin Pharmacol Ther 36, 824831.
66.Abernathy, DR & Greenblatt, DJ (1986) Drug disposition in obese humans: an update. Clin Pharmacokinet 11, 199213.
67.Caraco, Y, Zylber-Katz, E, Berry, EM et al. . (1995) Caffeine pharmacokinetics in obesity and following significant weight reduction. Int J Obes 19, 234239.
68.Hunt, CM, Watkins, PB & Saenger, P et al. . (1992) Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 51, 1823.
69.O'Shea, D, Davis, SN, Kim, RB et al. . (1994) Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 56, 359367.
70.Kotlyar, M & Carson, SW (1999) Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 37, 819.
71.Reiss, AR, Hass, CE, Karki, SD et al. . (1994) Lithium pharmacokinetics in the obese. Clin Pharmacol Ther 56, 392398.
72.Falagas, ME, Athanasoulia, AP, Peppas, G et al. . (2009) Effect of body mass index on the outcome of infections: a systematic review. Obesity 10, 280289.
73.Miller, JL, Johnson, PN, Harrison, DL et al. . (2010) Evaluation of inpatient admissions and potential antimicrobial and analgesic dosing errors in overweight children. Ann Pharmacother 44, 3542.
74.Traynor, AM, Nafziger, AN & Bertino, JS (1995) Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 39, 545548.
75.Bolme, P, Eriksson, M, Paazlow, L et al. . (1995) Malnutrition and pharmacokinetics of penicillin in Ethiopian children. Pharmacol Toxicol 76, 259262.
76.Buchanan, N, Robinson, R, Koornhof, HJ et al. . (1979) Penicillin pharmacokinetics in kwashiorkor. Am J Clin Nutr 32, 22332236.
77.Pussard, E, Barennes, H, Daouda, H et al. . (1999) Quinine disposition in globally malnourished children with cerebral malaria. Clin Pharmacol Ther 65, 500510.
78.Eriksson, M, Bolme, P, Habte, D et al. . (1988) INH and streptomycin in Ethiopian children with tuberculosis and different nutritional status. Acta Paediatr Scand 77, 890894.
79.Renton, KW (2001) Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92, 147163.
80.Boucher, BA, Wood, GC & Swanson, JM (2006) Pharmacokinetic changes in critical illness. Crit Care Clin 22, 255271.
81.Leader, WG, Tsubaki, T & Chandler, MHH (1994) Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. Am J Hosp Pharm 51, 2155–2130.
82.Gillum, JG, Johnson, M, Lavoie, S et al. . (1995) Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection. Pharmacotherapy 15, 251253.
83.Pittrow, L & Penk, A (1999) Special pharmacokinetics of fluconazole in septic, obese and burn patients. Mycoses 42, Suppl. 2, 8790.
84.Cohen, LG, DiBiasio, A, Lisco, SJ et al. . (1997) Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy 17, 10231026.
85.Kampmann, JP, Klein, H, Lumholtz, B et al. . (1984) Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to one year after operation. Clin Pharmacokinet 9, 168176.
86.Yuk, J, Nightengale, CH, Sweeney, K et al. (1988). Pharmacokinetics of nafcillin in obesity. J Infect Dis 157, 10881089.
87.Newman, D, Scheetz, MH, Adeyemi, OA et al. . (2007) Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother 41, 17341739.
88.Blouin, RA, Bauer, LA, Miller, DD et al. . (1982) Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 21, 575580.
89.Vance-Bryan, K, Guay, DR, Gilliland, SS et al. . (1993) Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 37, 436440.
90.Penzak, SR, Gubbins, PO, Rodvold, KA et al. . (1998) Therapeutic drug monitoring of vancomycin in a morbidly obese patient. Ther Drug Monit 20, 261265.
91.Mersfelder, TL & Smith, CL (2005) Linezolid pharmacokinetics in an obese patient [letter]. Am J Health-Syst Pharm 62, 464, 467.
92.Hernandez, JO, Norstrom, J & Wysock, G (2009) Acyclovir-induced renal failure in an obese patient. Am J Health-Syst Pharm 66, 12881291.
93.Falagas, ME & Karageorgopoulos, DE (2010) Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 375, 248251.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed